Rockwell Medical (NASDAQ:RMTI) Posts Earnings Results, Misses Expectations By $0.05 EPS

Rockwell Medical (NASDAQ:RMTI) released its quarterly earnings data on Thursday. The company reported ($0.01) EPS for the quarter, missing the consensus estimate of $0.04 by ($0.05), Zacks reports. Rockwell Medical had a negative net margin of 7.67% and a negative return on equity of 16.11%. The company had revenue of $18.35 million during the quarter, compared to analyst estimates of $18.58 million.

Here are the key takeaways from Rockwell Medical’s conference call:

• Rockwell reported structural operational improvements with Q4 gross margin rising to 21%, a positive full‑year Adjusted EBITDA, and $2.3M of operating cash flow in Q4, lifting year‑end cash to $25M.
• Net sales declined 32% YoY to $69.3M driven by reduced volumes from a major customer, contributing to a full‑year net loss of $5.3M (including non‑cash charges and restructuring costs).
• Customer diversification strengthened via multi‑year agreements (IRC, Concerto), long‑term supply to DCI, continued supply to Fresenius, a DaVita extension through end‑2026 with higher pricing, and ~30 new West Coast accounts gained after a competitor disruption.
• 2026 guidance targets Adjusted EBITDA of $1M–$2M and positive operating cash flow, with management noting ongoing negotiations with large customers that could further raise revenue and margins.
• Management reiterated a longer‑term ambition to exceed $100M in annual sales by 2029 with margins approaching ~30% and $5M–$10M in annual profit, but emphasized these are directional and subject to execution and market risks.

Rockwell Medical Stock Down 7.6%

Rockwell Medical stock opened at $0.87 on Friday. The company’s 50-day moving average price is $1.01 and its two-hundred day moving average price is $1.05. The company has a quick ratio of 3.50, a current ratio of 3.91 and a debt-to-equity ratio of 0.25. The stock has a market cap of $34.29 million, a P/E ratio of -5.80 and a beta of 1.71. Rockwell Medical has a twelve month low of $0.78 and a twelve month high of $2.10.

Institutional Trading of Rockwell Medical

Several hedge funds have recently added to or reduced their stakes in RMTI. Geode Capital Management LLC grew its holdings in Rockwell Medical by 12.9% in the 4th quarter. Geode Capital Management LLC now owns 364,816 shares of the company’s stock valued at $304,000 after buying an additional 41,668 shares in the last quarter. XTX Topco Ltd grew its stake in shares of Rockwell Medical by 286.5% in the fourth quarter. XTX Topco Ltd now owns 62,097 shares of the company’s stock valued at $52,000 after acquiring an additional 46,029 shares in the last quarter. Jane Street Group LLC bought a new position in Rockwell Medical during the fourth quarter worth about $84,000. Finally, Vanguard Group Inc. boosted its holdings in Rockwell Medical by 12.3% in the 3rd quarter. Vanguard Group Inc. now owns 1,354,147 shares of the company’s stock valued at $1,625,000 after purchasing an additional 148,737 shares during the period. 23.31% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

RMTI has been the subject of a number of recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $2.50 price target on shares of Rockwell Medical in a research note on Monday, January 26th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rockwell Medical in a research note on Thursday, January 22nd. Finally, Wall Street Zen upgraded Rockwell Medical from a “sell” rating to a “hold” rating in a report on Saturday. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Rockwell Medical currently has an average rating of “Hold” and an average price target of $2.50.

Key Stories Impacting Rockwell Medical

Here are the key news stories impacting Rockwell Medical this week:

• Positive Sentiment: Achieved adjusted EBITDA profitability for the second straight year, showing improved operating leverage that can support the path to sustainable profitability. Rockwell Medical Announces Fourth Quarter and Full-Year 2025 Financial and Operational Results
• Positive Sentiment: Featured in Zacks screens as a value/momentum candidate — this can attract bargain hunters and momentum traders looking for turnaround stories. Should Value Investors Buy Rockwell Medical (RMTI) Stock?
• Neutral Sentiment: Full Q4 earnings call/transcript provides management commentary and color on drivers of the quarter and the FY26 outlook — useful for investors who want to hear management’s execution plan and assumptions. Rockwell Medical, Inc. (NASDAQ:RMTI) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Q4 results missed revenue estimates and reported EPS came in below some consensus figures, signaling slower top‑line momentum; several outlets flagged the revenue decline as the main driver of investor concern. Rockwell Medical (RMTI) Reports Q4 Loss, Misses Revenue Estimates
• Negative Sentiment: Management’s cost‑cutting/right‑sizing plan has raised execution risk and could pressure future growth if not managed carefully — analysts flagged this as a demand/execution risk that may weigh on investor confidence. Rockwell Medical’s Cost Cuts Raise Execution Risk and Threaten Future Growth Prospects
• Negative Sentiment: Company issued a FY26 outlook that some market coverage characterized as cautious after the quarter; investors typically punish missed top‑line results and uncertain guidance more than one‑time positives. Rockwell Medical misses top-line estimates; gives FY26 outlook

About Rockwell Medical

Rockwell Medical, Inc is a Delaware‐domiciled biopharmaceutical company focused on the development and commercialization of therapies for patients with chronic kidney disease (CKD). The company’s mission centers on addressing common complications in CKD—namely iron deficiency and secondary hyperparathyroidism—through innovative treatment approaches designed for dialysis settings.

The company’s lead product, TRIFERIC®, is an iron replacement therapy approved by the U.S. Food and Drug Administration for use in hemodialysis patients.